Betuvax

Betuvax is a Russian biotechnology company and a subsidiary of Artgen Biotech that specializes in the development of next-generation subunit vaccines. The company's core technology is the proprietary Betusphere platform, which utilizes betulin-based spherical nanoparticles as both a carrier and an adjuvant to enhance the immunogenicity and safety of recombinant protein antigens. Its lead candidate, Betuvax-CoV-2, is a recombinant protein subunit vaccine for COVID-19 that has successfully completed Phase 1/2 clinical trials, demonstrating a favorable safety profile and strong humoral response. Beyond COVID-19, Betuvax is advancing a diverse pipeline of vaccines targeting influenza, human papillomavirus (HPV), rotavirus, and common respiratory allergies. The company operates within the Skolkovo Innovation Center and collaborates with strategic partners like RBT and Nacimbio to bring its innovative immunotherapies to market.